Clinical Scorecard: Kaempferol Modulates HSP70–Beclin-1 Interaction in a Dose-Dependent Manner, Influencing Autophagy and Chemotherapy Response
At a Glance
Category
Detail
Condition
Key Mechanisms
Dose-dependent modulation of HSP70–Beclin-1 complex affecting autophagy and chemotherapy response, as demonstrated in both in vitro and in vivo studies.
Target Population
Care Setting
Key Highlights
Low-dose kaempferol stabilizes HSP70–Beclin-1, suppressing autophagy and apoptosis.
High-dose kaempferol disrupts HSP70–Beclin-1, enhancing autophagic flux and chemosensitivity.
Kaempferol's effects are mediated through AMPK/mTOR inhibition and ER stress–JNK signaling.
Dose-dependent effects of kaempferol provide insights for optimizing natural product therapies.
Study highlights the potential of kaempferol in enhancing cisplatin's antitumor activity, supported by in vivo evidence.
Guideline-Based Recommendations
Diagnosis
Management
Consider kaempferol dosing strategies (e.g., low vs. high dose) to modulate autophagy in conjunction with chemotherapy.
Monitoring & Follow-up
Risks
Patient & Prescribing Data
Kaempferol may be used to enhance the effectiveness of cisplatin through autophagy modulation, but caution is advised regarding potential risks.
Clinical Best Practices
Evaluate the dose-response relationship of kaempferol in clinical settings, using specific autophagy markers for assessment.
